Literature DB >> 25244551

Characterization and outcomes of repeat orbital decompression for thyroid-associated orbitopathy.

Sandy X Zhang-Nunes1, Sabin Dang, Helene Chokron Garneau, Catherine Hwang, David Isaacs, Shu-Hong Chang, Robert Goldberg.   

Abstract

Orbital decompression for thyroid-associated orbitopathy (TAO) is commonly performed for disfiguring proptosis, congestion, and optic neuropathy. Although one decompression typically achieves goals, a small percentage requires repeat decompression. We performed a 10-year retrospective chart review of all orbital decompressions for TAO at a single tertiary referral institution. Four-hundred and ninety-five orbits (330 patients) were decompressed for TAO, with 45 orbits (37 patients) requiring repeat decompression. We reviewed the repeat cases for indications, clinical activity scores, approach, walls decompressed, and outcomes. Nine percent of orbits required repeat decompression for proptosis (70%), optic neuropathy (25%) or congestion (45%). Sixty-four percent were for recurrence of disease, 36% were for suboptimal decompression. Three incisional approaches were used: lateral upper eyelid crease, inferior transconjunctival, and transcaruncular, with inferior transconjunctival being most common. Of the three walls removed, deep lateral, inferior, and medial, the deep lateral wall was most common (51%). A repeat lateral decompression was the most frequent pattern. Of 37 patients requiring repeat decompression, 40% had diplopia prior to repeat, and an additional 24% developed diplopia after the repeat. Whereas previous studies published by our group cited only 2.6% of deep lateral wall orbital decompressions leading to new-onset primary gaze diplopia, repeat orbital decompressions have a much higher rate of post-operative diplopia. The new onset primary gaze diplopia after repeat decompression group had a higher average preoperative CAS (3.3 vs. 2.4, p < 0.01), higher mean blood loss (56 vs. 19 mL, p = 0.04), more frequent medial wall decompressions (47% vs. 29%, p = 0.33), and greater proptosis reduction (2.4 vs. 1.7 mm, p = 0.24).

Entities:  

Keywords:  Diplopia; Graves’ disease; orbital decompression; repeat; thyroid ophthalmopathy

Mesh:

Year:  2014        PMID: 25244551     DOI: 10.3109/01676830.2014.949784

Source DB:  PubMed          Journal:  Orbit        ISSN: 0167-6830


  6 in total

1.  Preoperative clinical features of reactivated of Graves' orbitopathy after orbital decompression.

Authors:  Y J Woo; J W Kim; J S Yoon
Journal:  Eye (Lond)       Date:  2017-01-06       Impact factor: 3.775

2.  [Orbital decompression : Indications, technique, results].

Authors:  H-J Welkoborsky; S K Graß; J Küstermeyer; K V Steinke
Journal:  HNO       Date:  2017-12       Impact factor: 1.284

3.  The effect of intravenous high-dose glucocorticoids and orbital decompression surgery on sight-threatening thyroid-associated ophthalmopathy.

Authors:  Yun Wen; Jian-Hua Yan
Journal:  Int J Ophthalmol       Date:  2019-11-18       Impact factor: 1.779

4.  Thyroid-Related Orbital Decompression Surgery: A Multivariate Analysis of Risk Factors and Outcomes.

Authors:  Chris Y Wu; Leslie M Niziol; David C Musch; Alon Kahana
Journal:  Ophthalmic Plast Reconstr Surg       Date:  2017 May/Jun       Impact factor: 1.746

5.  Tear proteomics of orbital decompression for disfiguring exophthalmos in inactive thyroid-associated ophthalmopathy.

Authors:  Lihong Jiang; Ao Rong; Ruili Wei; Jiale Diao; Hui Ding; Wei Wang
Journal:  Exp Ther Med       Date:  2020-10-23       Impact factor: 2.447

6.  Teprotumumab in advanced reactivated thyroid eye disease.

Authors:  Olivia T Cheng; Dianne M Schlachter
Journal:  Am J Ophthalmol Case Rep       Date:  2022-03-15
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.